Photonic technologies are recognised as key enablers to satisfy the flexibility, SWaP and performance requirements of next generation EO missions. The ability of Photonics to handle high data rates and high frequencies and its easy reconfigurability is critical in this scenario, where current purely RF technologies are limited in SWaP and performance. However, the use of Photonics is currently restricted to a few demonstrations in non-critical equipment, due to their perceived immaturity compared to RF. RETINA will develop several key RF-photonic building blocks to TRL5-6, designing, fabricating and testing 1) multi-beam TTD phased array antennas for X band operation, 2) a photonic integrated beamforming network, 3) novel configuration active X-band antenna array and 4) miniaturized space-grade components and subsystems. Miniaturization will be achieved by integrating lasers and external modulators with electronics in the Tx side, integrating photodiodes, amplifiers and electronics at the Rx side and by fabricating a PIC beamformer. RETINA will integrate and demonstrate such building blocks in a test bed proving the suitability of the proposed architecture in a SAR scenario for 64 beams, demonstrating a flexible SAR payload for missions requiring flexible frequency plans and channelization and dynamic coverage operation. RETINA consortium comprises the multidisciplinary skills needed to achieve its objectives and fully exploit its results, with partners representing the whole value chain, from space-grade hardware developers to EO satellite integrators and by Academia Partners developing key technologies and fostering technology transfer. RETINA builds on the results of FP7 project GAIA and is complementary to developments made by its partners in ESA and EC Projects. RETINA success will contribute to enhance EU competitiveness and non-dependence by developing critical technologies for the EU satellite industry that can be transferred to non-space sectors.

Drug hypersensitivity to antibiotics, mainly Beta-lactams (BLCs) affects more than 2.5 million European citizens. Moreover, preventable adverse drug reactions are estimated in additional hospitalization costs of 1750-4500 €/patient. Currently, the allergy diagnosis is mainly based on the information given by invasive, single, and risky in vivo assays. In daily practice, few in vitro diagnostic methods are available and only used at the tertiary health services. These tests also lack of sensitivity (>0.35 kUA/L) and selectivity (98%), multiplexed (10 BLCs), rapid (30 min), and low-cost (2.4 €/allergen) drug allergy test. The solution involves an advanced approach to the diagnosis and management of drug allergy with the aim to ameliorate patient safety. The consortium comprises multidisciplinary knowledge on optics, electronics, advanced materials, biotechnology, smart microstructures, microfluidics, surface/organic chemistry, allergy, manufacturing systems, and telecom networking. Also, the key industrial actors, present in the consortium, will contribute to the manufacturing and placing the product on the IVD market.